Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
PLoS One ; 13(12): e0209489, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-30576337

RESUMEN

Osteosarcoma (OSA) is an aggressive mesenchymal tumor of the bone that affects children and occurs spontaneously in dogs. Human and canine OSA share similar clinical, biological and genetic features, which make dogs an excellent comparative model to investigate the etiology and pathogenesis of OSA. Mitochondrial (mt) defects have been reported in many different cancers including OSA, although it is not known whether these defects contribute to OSA progression and metastasis. Taking a comparative approach using canine OSA cell lines and tumor tissues we investigated the effects of mtDNA content and dysfunction on OSA biology. OSA tumor tissues had low mtDNA contents compared to the matched non-tumor tissues. We observed mitochondrial heterogeneity among the OSA cell lines and the most invasive cells expressing increased levels of OSA metastasis genes contained the highest amount of mitochondrial defects (reduced mtDNA copies, mt respiration, and expression of electron transport chain proteins). While mitochondria maintain a filamentous network in healthy cells, the mitochondrial morphology in OSA cells were mostly "donut shaped", typical of "stressed" mitochondria. Moreover the expression levels of mitochondrial retrograde signaling proteins Akt1, IGF1R, hnRNPA2 and NFkB correlated with the invasiveness of the OSA cells. Furthermore, we demonstrate the causal role of mitochondrial defects in inducing the invasive phenotype by Ethidium Bromide induced-mtDNA depletion in OSA cells. Our data suggest that defects in mitochondrial genome and function are prevalent in OSA and that lower mtDNA content is associated with higher tumor cell invasiveness. We propose that mt defects in OSA might serve as a prognostic biomarker and a target for therapeutic intervention in OSA patients.


Asunto(s)
Neoplasias Óseas/genética , Enfermedades de los Perros/genética , Genoma Mitocondrial , Osteosarcoma/genética , Animales , Biomarcadores de Tumor/genética , Biomarcadores de Tumor/aislamiento & purificación , Biomarcadores de Tumor/metabolismo , Biopsia , Neoplasias Óseas/patología , Neoplasias Óseas/terapia , Neoplasias Óseas/veterinaria , Vacunas contra el Cáncer/uso terapéutico , Carboplatino/uso terapéutico , Línea Celular Tumoral , ADN Mitocondrial/genética , ADN Mitocondrial/aislamiento & purificación , ADN Mitocondrial/metabolismo , Enfermedades de los Perros/patología , Enfermedades de los Perros/terapia , Perros , Etidio/toxicidad , Mitocondrias/efectos de los fármacos , Mitocondrias/genética , Invasividad Neoplásica/genética , Osteosarcoma/patología , Osteosarcoma/terapia , Osteosarcoma/veterinaria , Pronóstico , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...